ロード中...
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-α2a for the treatment of patients with metastatic renal cell carcinoma. The approval was primarily based on re...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227879/ https://ncbi.nlm.nih.gov/pubmed/20061402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0250 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|